For: | Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, Wang H. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(32): 3745-3751 [PMID: 21990957 DOI: 10.3748/wjg.v17.i32.3745] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i32/3745.htm |
Number | Citing Articles |
1 |
Marilena Karavyraki, Richard K. Porter. Evidence of a role for interleukin-6 in anoikis resistance in oral squamous cell carcinoma. Medical Oncology 2022; 39(6) doi: 10.1007/s12032-022-01664-5
|
2 |
Runzhi Huang, Zehui Sun, Shuyuan Xian, Dianwen Song, Zhengyan Chang, Penghui Yan, Jie Zhang, Huabin Yin, Zixuan Zheng, Peng Hu, Zhenyu Li, Dan Huang, Yihan Liu, Chenyang Jiang, Man Li, Siqi Li, Tong Meng, Daoke Yang, Zongqiang Huang. The role of toll-like receptors (TLRs) in pan-cancer. Annals of Medicine 2022; 54(1): 1918 doi: 10.1080/07853890.2022.2095664
|
3 |
Ryma Haroun, Sahar Naasri, Ayman J. Oweida. Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities. Vaccines 2023; 11(4): 818 doi: 10.3390/vaccines11040818
|
4 |
Xinxin Guo, Ping Wan, Weitao Shen, Mingjun Sun, Zhenyan Peng, Yinghao Liao, Yang Huang, Ran Liu. Fusobacterium periodonticum BCT protein targeting glucose metabolism to promote the epithelial-mesenchymal transition of esophageal cancer cells by lactic acid. Journal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-05157-z
|
5 |
Khan Shahanavaj, Ignacio Gil-Bazo, Marta Castiglia, Giuseppe Bronte, Francesco Passiglia, Anna P Carreca, José Luis del Pozo, Antonio Russo, Marc Peeters, Christian Rolfo. Cancer and the microbiome: potential applications as new tumor biomarker. Expert Review of Anticancer Therapy 2015; 15(3): 317 doi: 10.1586/14737140.2015.992785
|
6 |
Heikki Huhta, Olli Helminen, Petri P. Lehenkari, Juha Saarnio, Tuomo J. Karttunen, Joonas H. Kauppila. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma. Oncotarget 2016; 7(17): 23658 doi: 10.18632/oncotarget.8151
|
7 |
Liang Chang, Fengjie Guo, Yalei Lv, Yudong Wang, Bingjie Huo, Long Wang, Wei Liu. The inhibitory effects of Endostar combined with chemotherapy on human esophageal squamous cell carcinoma xenograft in mice. Molecular Biology Reports 2013; 40(1): 669 doi: 10.1007/s11033-012-2106-x
|
8 |
|
9 |
Manaswita Saikia, Dhruba K. Bhattacharyya, Jugal K. Kalita. CBDCEM: An effective centrality based differential co-expression method for critical gene finding. Gene Reports 2022; 29: 101688 doi: 10.1016/j.genrep.2022.101688
|
10 |
Qiong Dai, Xing Pu Li, Li Chai, Han An Long, Zhi Hui Yang. Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility. Tumor Biology 2014; 35(4): 3247 doi: 10.1007/s13277-013-1424-5
|
11 |
Daye Cheng, Yiwen Hao, Wenling Zhou, Yiran Ma. Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis. Tumor Biology 2014; 35(8): 7837 doi: 10.1007/s13277-014-2049-z
|
12 |
Yukun Zu, Wei Ping, Taoran Deng, Ni Zhang, Xiangning Fu, Wei Sun. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression. Diseases of the Esophagus 2016; doi: 10.1111/dote.12466
|
13 |
Johanna C. Klein, Katrin Moses, Gennadiy Zelinskyy, Simon Sody, Jan Buer, Stephan Lang, Iris Helfrich, Ulf Dittmer, Carsten J. Kirschning, Sven Brandau. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nature Communications 2017; 8(1) doi: 10.1038/ncomms14600
|
14 |
Sedigheh Baakhlagh, Bahareh Kashani, Zahra Zandi, Davood Bashash, Malihe Moradkhani, Ali Nasrollahzadeh, Marjan Yaghmaei, Seyed A. Mousavi, Seyed H. Ghaffari. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation. International Immunopharmacology 2021; 90: 107202 doi: 10.1016/j.intimp.2020.107202
|
15 |
Cindy Patinote, Nour Bou Karroum, Georges Moarbess, Natalina Cirnat, Issam Kassab, Pierre-Antoine Bonnet, Carine Deleuze-Masquéfa. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. European Journal of Medicinal Chemistry 2020; 193: 112238 doi: 10.1016/j.ejmech.2020.112238
|
16 |
A.A. Khan, Z. Khan, S. Warnakulasuriya. Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?. Annals of Oncology 2016; 27(6): 984 doi: 10.1093/annonc/mdw053
|
17 |
|
18 |
Vinita Mishra, Chandramani Pathak. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. International Journal of Biological Macromolecules 2019; 122: 425 doi: 10.1016/j.ijbiomac.2018.10.142
|
19 |
Ju‐Hee Han, Shin‐Young Park, Jin‐Bum Kim, Sung‐Dae Cho, Bumseok Kim, Bo‐Yeon Kim, Min‐Jung Kang, Dong‐Jae Kim, Jae‐Hak Park, Jong‐Hwan Park. TLR7 Expression is Decreased During Tumour Progression in Transgenic Adenocarcinoma of Mouse Prostate Mice and Its Activation Inhibits Growth of Prostate Cancer Cells. American Journal of Reproductive Immunology 2013; 70(4): 317 doi: 10.1111/aji.12146
|
20 |
Bahareh Kashani, Zahra Zandi, Mohammad Reza Karimzadeh, Davood Bashash, Ali Nasrollahzadeh, Seyed H. Ghaffari. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Immunologic Research 2019; 67(6): 505 doi: 10.1007/s12026-019-09113-8
|
21 |
Hao Sun, Yingmei Li, Peng Zhang, Haizhou Xing, Song Zhao, Yongping Song, Dingming Wan, Jifeng Yu. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives. Biomarker Research 2022; 10(1) doi: 10.1186/s40364-022-00436-7
|
22 |
Olaia Akesolo, Berta Buey, Manuel Beltrán-Visiedo, David Giraldos, Isabel Marzo, Eva Latorre. Toll-like receptors: New targets for multiple myeloma treatment?. Biochemical Pharmacology 2022; 199: 114992 doi: 10.1016/j.bcp.2022.114992
|
23 |
Romy E. Verbeek, Peter D. Siersema, Fiebo J. Ten Kate, Kees Fluiter, Rhonda F. Souza, Frank P. Vleggaar, Pauline Bus, Jantine W. P. M. van Baal. Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expression. Journal of Gastroenterology 2014; 49(7): 1121 doi: 10.1007/s00535-013-0862-6
|
24 |
Michael Linnebacher, Claudia Maletzki, Ulrike Klier, Ernst Klar. Bacterial immunotherapy of gastrointestinal tumors. Langenbeck's Archives of Surgery 2012; 397(4): 557 doi: 10.1007/s00423-011-0892-6
|
25 |
Yasuhiro Nihon-Yanagi, Megumi Wakayama, Naobumi Tochigi, Fumi Saito, Hideaki Ogata, Kazutoshi Shibuya, Anjali Mishra. Immunohistochemical Analysis of Toll-Like Receptors, MyD88, and TRIF in Human Papillary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Journal of Thyroid Research 2021; 2021: 1 doi: 10.1155/2021/4226491
|
26 |
Haoyang Zheng, Peiyang Wu, Pierre-Antoine Bonnet. Recent Advances on Small-Molecule Antagonists Targeting TLR7. Molecules 2023; 28(2): 634 doi: 10.3390/molecules28020634
|
27 |
Fatma E. Mohamed, Rajai M. Al‐Jehani, Shane S. Minogue, Fausto Andreola, Alison Winstanley, Steven W.M. Olde Damink, Abeba Habtesion, Massimo Malagó, Nathan Davies, Tu Vinh Luong, Amar P. Dhillon, Rajeshwar P. Mookerjee, Dipok K. Dhar, Rajiv Jalan. Effect of toll‐like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver International 2015; 35(3): 1063 doi: 10.1111/liv.12626
|
28 |
Zahra Zandi, Bahareh Kashani, Ensieh M. Poursani, Davood Bashash, Majid Kabuli, Majid Momeny, Seyedeh H. Mousavi-pak, Fatemeh Sheikhsaran, Kamran Alimoghaddam, Seyed A. Mousavi, Seyed H. Ghaffari. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition. European Journal of Pharmacology 2019; 853: 256 doi: 10.1016/j.ejphar.2019.03.046
|
29 |
Lauri Jouhi, Neeta Datta, Suvi Renkonen, Timo Atula, Antti Mäkitie, Caj Haglund, Abdirisak Ahmed, Stina Syrjänen, Reidar Grénman, Eeva Auvinen, Sanna Lehtonen, Jaana Hagström. Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma—an in vivo and in vitro study. Tumor Biology 2015; 36(10): 7755 doi: 10.1007/s13277-015-3494-z
|
30 |
E. Visser, I. A. Franken, L. A. A. Brosens, W. W. J. de Leng, E. Strengman, J. A. Offerhaus, J. P. Ruurda, R. van Hillegersberg. Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival. Diseases of the Esophagus 2017; 30(9): 1 doi: 10.1093/dote/dox058
|
31 |
Shengwei Han, Wenguang Xu, Zhiyong Wang, Xiaofeng Qi, Yufeng Wang, Yanhong Ni, Hao Shen, Qingang Hu, Wei Han. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment. Oncotarget 2016; 7(25): 37773 doi: 10.18632/oncotarget.9329
|
32 |
Lei Li, Feng-Wei Cheng, Fang Wang, Bo Jia, Xin Luo, Sheng-Quan Zhang. The activation of TLR7 regulates the expression of VEGF, TIMP1, MMP2, IL-6, and IL-15 in Hela cells. Molecular and Cellular Biochemistry 2014; 389(1-2): 43 doi: 10.1007/s11010-013-1925-y
|
33 |
James O. Jones, William M. Moody, Jacqueline D. Shields. Microenvironmental modulation of the developing tumour: an immune‐stromal dialogue. Molecular Oncology 2021; 15(10): 2600 doi: 10.1002/1878-0261.12773
|
34 |
Xiaoyu Wang, Yu Chen, Steven Zhang, Jinxia Nancy Deng, Anand Gaurav. Molecular dynamics simulations reveal the selectivity mechanism of structurally similar agonists to TLR7 and TLR8. PLOS ONE 2022; 17(4): e0260565 doi: 10.1371/journal.pone.0260565
|
35 |
Jiaying Li, Hongjiao Wu, Hui Gao, Ruihuan Kou, Yuning Xie, Zhi Zhang, Xuemei Zhang. TLR4 promoter rs1927914 variant contributes to the susceptibility of esophageal squamous cell carcinoma in the Chinese population. PeerJ 2021; 9: e10754 doi: 10.7717/peerj.10754
|
36 |
Zhifeng He, Xiaofeng Huang, Yanhong Ni, Peihua Shi, Zhiyong Wang, Wei Han, Qingang Hu. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014; 118(1): 92 doi: 10.1016/j.oooo.2014.03.012
|
37 |
Yongbin Jing, Mingkun Jia, Jinpeng Zhuang, Dong Han, Changlong Zhou, Jinglong Yan. TLR9 Exerts an Oncogenic Role in Promoting Osteosarcoma Progression Depending on the Regulation of NF-κB Signaling Pathway. Biological and Pharmaceutical Bulletin 2022; 45(12): 1733 doi: 10.1248/bpb.b22-00295
|
38 |
Shaherin Basith, Balachandran Manavalan, Tae Hyeon Yoo, Sang Geon Kim, Sangdun Choi. Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense. Archives of Pharmacal Research 2012; 35(8): 1297 doi: 10.1007/s12272-012-0802-7
|
39 |
Shrabon Hasnat, Roosa Hujanen, Bright I. Nwaru, Tuula Salo, Abdelhakim Salem. The Prognostic Value of Toll-Like Receptors in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 2020; 21(19): 7255 doi: 10.3390/ijms21197255
|
40 |
Qian Zhang, Jun Dan, Shuang Meng, Yingjie Li, Jing Li. TLR4 inhibited autophagy by modulating PI3K/AKT/mTOR signaling pathway in Gastric cancer cell lines. Gene 2023; 876: 147520 doi: 10.1016/j.gene.2023.147520
|
41 |
Andrés H. Rossi, Ana Farias, Javier E. Fernández, Hernán R. Bonomi, Fernando A. Goldbaum, Paula M. Berguer, Andrzej T Slominski. Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLOS ONE 2015; 10(5): e0126827 doi: 10.1371/journal.pone.0126827
|
42 |
Yuan Liu, Xiaodong Guo, Liyuan Wu, Mei Yang, Zhiwei Li, Yinjie Gao, Shuhong Liu, Guangde Zhou, Jingmin Zhao. Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget 2016; 7(39): 63856 doi: 10.18632/oncotarget.11697
|
43 |
Taru Ilmarinen, Jaana Hagström, Caj Haglund, Eeva Auvinen, Ilmo Leivo, Anne Pitkäranta, Leena‐Maija Aaltonen. Low Expression of Nuclear Toll‐like Receptor 4 in Laryngeal Papillomas Transforming into Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery 2014; 151(5): 785 doi: 10.1177/0194599814549730
|
44 |
Yao Liu, Hao Chen, Zheng Sun, Xiaoxin Chen. Molecular mechanisms of ethanol-associated oro-esophageal squamous cell carcinoma. Cancer Letters 2015; 361(2): 164 doi: 10.1016/j.canlet.2015.03.006
|
45 |
Kai Wu, Yang Yang, Donglei Liu, Yu Qi, Chunyang Zhang, Jia Zhao, Song Zhao. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway. Oncotarget 2016; 7(28): 44572 doi: 10.18632/oncotarget.10067
|
46 |
Bin Zhao, Xiulong Niu, Suhui Huang, Jing Yang, Yiyi Wei, Xiujuan Wang, Junhong Wang, Yue Wang, Xiaoqin Guo, Ulises Urzua. TLR4 Agonist and Hypoxia Synergistically Promote the Formation of TLR4/NF-κB/HIF-1α Loop in Human Epithelial Ovarian Cancer. Analytical Cellular Pathology 2022; 2022: 1 doi: 10.1155/2022/4201262
|
47 |
Yan Wang, Jinnan Zhang, Wei Zhao, Donglin Wang, Wenduan Ma, Shengtao Shang, Chao Feng, Haixin Yu. MicroRNA expression in esophageal squamous cell carcinoma: Novel diagnostic and prognostic biomarkers. Molecular Medicine Reports 2017; 15(6): 3833 doi: 10.3892/mmr.2017.6479
|
48 |
Prapti Shrestha, Ross Penninkilampi, Guy D. Eslick. Gastrointestinal Diseases and their Associated Infections. 2019; : 1 doi: 10.1016/B978-0-323-54843-4.00001-5
|
49 |
Sanjay Pandey, Saurabh Singh, Vandana Anang, Anant N. Bhatt, K. Natarajan, Bilikere S. Dwarakanath. Pattern Recognition Receptors in Cancer Progression and Metastasis. Cancer Growth and Metastasis 2015; 8: CGM.S24314 doi: 10.4137/CGM.S24314
|
50 |
Xin Zheng, Song Li, Hui Yang. Roles of Toll-Like Receptor 3 in Human Tumors. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.667454
|
51 |
Ximena Maria Muresan, Jan Bouchal, Zoran Culig, Karel Souček. Toll-Like Receptor 3 in Solid Cancer and Therapy Resistance. Cancers 2020; 12(11): 3227 doi: 10.3390/cancers12113227
|
52 |
Mou Wang, Yuejing Wang, Renhe Liu, Ruilian Yu, Tao Gong, Zhirong Zhang, Yao Fu. TLR4 Blockade Using Docosahexaenoic Acid Restores Vulnerability of Drug-Tolerant Tumor Cells and Prevents Breast Cancer Metastasis and Postsurgical Relapse. ACS Bio & Med Chem Au 2023; 3(1): 97 doi: 10.1021/acsbiomedchemau.2c00061
|
53 |
JIONG JIANG, LEI DONG, BIN QIN, HAITAO SHI, XIAOYAN GUO, YAN WANG. Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncology Letters 2016; 12(1): 631 doi: 10.3892/ol.2016.4617
|
54 |
K. Nesteruk, M.C.W. Spaander, I. Leeuwenburgh, M.P. Peppelenbosch, G.M. Fuhler. Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett's–associated adenocarcinoma?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2019; 1872(2): 188291 doi: 10.1016/j.bbcan.2019.04.007
|
55 |
D Jia, W Yang, L Li, H Liu, Y Tan, S Ooi, L Chi, L G Filion, D Figeys, L Wang. β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer. Cell Death & Differentiation 2015; 22(2): 298 doi: 10.1038/cdd.2014.145
|
56 |
Vasiliki Koliaraki, Ana Henriques, Alejandro Prados, George Kollias. Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. Journal of Experimental Medicine 2020; 217(4) doi: 10.1084/jem.20190457
|
57 |
Abdul Arif Khan, Abhinav Shrivastava, Mohsin Khurshid. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2012; 1826(2): 331 doi: 10.1016/j.bbcan.2012.05.005
|
58 |
Aadil Sheikh, Joseph Taube, K Leigh Greathouse. Contribution of the microbiota and their secretory products to inflammation and colorectal cancer pathogenesis: the role of toll-like receptors. Carcinogenesis 2021; 42(9): 1133 doi: 10.1093/carcin/bgab060
|
59 |
Yazdan Mokhtari, Atieh Pourbagheri‐Sigaroodi, Parisa Zafari, Nader Bagheri, Seyed H. Ghaffari, Davood Bashash. Toll‐like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. Journal of Cellular and Molecular Medicine 2021; 25(2): 639 doi: 10.1111/jcmm.16214
|
60 |
Jun Wei Ng, Eric Tzyy Jiann Chong, Ping-Chin Lee. An Updated Review on the Role of Single Nucleotide Polymorphisms in
COVID-19 Disease Severity: A Global Aspect. Current Pharmaceutical Biotechnology 2022; 23(13): 1596 doi: 10.2174/1389201023666220114162347
|
61 |
Hyun-ju Lee, Hee-Jeong Choi, Yoo Joo Jeong, Yoon-Hee Na, Jin Tae Hong, Ji Min Han, Hyang-Sook Hoe, Key-Hwan Lim. Developing theragnostics for Alzheimer's disease: Insights from cancer treatment. International Journal of Biological Macromolecules 2024; 269: 131925 doi: 10.1016/j.ijbiomac.2024.131925
|
62 |
Carlene Petes, Natalya Odoardi, Katrina Gee. The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome. Frontiers in Immunology 2017; 8 doi: 10.3389/fimmu.2017.01075
|
63 |
Solmaz Ohadian Moghadam, Mohammad Reza Nowroozi. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy. Scandinavian Journal of Immunology 2019; 90(6) doi: 10.1111/sji.12818
|
64 |
Richard E. Kast. The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive. International Journal of Molecular Sciences 2023; 24(20): 15474 doi: 10.3390/ijms242015474
|
65 |
Xiaohong Cen, Shuwen Liu, Kui Cheng. The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.00878
|
66 |
Zuzanna Urban-Wojciuk, Mohd M. Khan, Benjamin L. Oyler, Robin Fåhraeus, Natalia Marek-Trzonkowska, Aleksandra Nita-Lazar, Ted R. Hupp, David R. Goodlett. The Role of TLRs in Anti-cancer Immunity and Tumor Rejection. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02388
|
67 |
Tanja Grimmig, Romana Moench, Jennifer Kreckel, Stephanie Haack, Felix Rueckert, Roberta Rehder, Sudipta Tripathi, Carmen Ribas, Anil Chandraker, Christoph Germer, Martin Gasser, Ana Waaga-Gasser. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. International Journal of Molecular Sciences 2016; 17(12): 2060 doi: 10.3390/ijms17122060
|
68 |
Da-Wei Yeh, Li-Rung Huang, Ya-Wen Chen, Chi-Ying F. Huang, Tsung-Hsien Chuang. Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. Journal of Immunology Research 2016; 2016: 1 doi: 10.1155/2016/4368101
|
69 |
S. D. Gowing, J. J. Cool-Lartigue, J. D. Spicer, A. J. E. Seely, L. E. Ferri. Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence. Clinical & Experimental Metastasis 2020; 37(2): 225 doi: 10.1007/s10585-020-10018-2
|
70 |
Jing Liu, Yanbo Wang, Yanjie Chu, Ruiling Xu, Dekai Zhang, Xinhong Wang. Identification of a TLR-Induced Four-lncRNA Signature as a Novel Prognostic Biomarker in Esophageal Carcinoma. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00649
|
71 |
Fabiana Olímpio, Robert Andreata-Santos, Paloma Cristina Rosa, Wellington Santos, Carlos Oliveira, Flavio Aimbire. Lactobacillus rhamnosus Restores Antiviral Signaling and Attenuates Cytokines Secretion from Human Bronchial Epithelial Cells Exposed to Cigarette Smoke and Infected with SARS-CoV-2. Probiotics and Antimicrobial Proteins 2023; 15(6): 1513 doi: 10.1007/s12602-022-09998-2
|
72 |
Yan Hong Ni, Liang Ding, Dong Ya Zhang, Ya Yi Hou, Xiaofeng Huang, Qingang Hu. Distinct expression patterns of Toll‐like receptor 7 in tumour cells and fibroblast‐like cells in oral squamous cell carcinoma. Histopathology 2015; 67(5): 730 doi: 10.1111/his.12703
|
73 |
Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview. Biomedicines 2022; 11(1): 64 doi: 10.3390/biomedicines11010064
|
74 |
Jinrui Wei, Yan Zhang, Haopeng Li, Fuquan Wang, Shanglong Yao. Toll-like receptor 4: A potential therapeutic target for multiple human diseases. Biomedicine & Pharmacotherapy 2023; 166: 115338 doi: 10.1016/j.biopha.2023.115338
|
75 |
Joonas H. Kauppila, Katri S. Selander. Toll-Like Receptors in Esophageal Cancer. Frontiers in Immunology 2014; 5 doi: 10.3389/fimmu.2014.00200
|
76 |
Guangcan Chen, Muming Xu, Jingyao Chen, Liangli Hong, Wenting Lin, Shukun Zhao, Guohong Zhang, Guo Dan, Shuhui Liu. Clinicopathological Features and Increased Expression of Toll-Like Receptor 4 of Gastric Cardia Cancer in a High-Risk Chinese Population. Journal of Immunology Research 2018; 2018: 1 doi: 10.1155/2018/7132868
|
77 |
Saran Aravinda Chandrasekar, Thirunavukkarasu Palaniyandi, Udhayakumar Parthasarathy, Hemapreethi Surendran, Sandhiya Viswanathan, Mugip Rahaman Abdul Wahab, Gomathy Baskar, Sudhakar Natarajan, Kishu Ranjan. Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers. Pathology - Research and Practice 2023; 248: 154673 doi: 10.1016/j.prp.2023.154673
|
78 |
Lisa A. Ridnour, Robert Y.S. Cheng, Christopher H. Switzer, Julie L. Heinecke, Stefan Ambs, Sharon Glynn, Howard A. Young, Giorgio Trinchieri, David A. Wink. Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment—Poor Prognosis or New Therapeutic Opportunity. Clinical Cancer Research 2013; 19(6): 1340 doi: 10.1158/1078-0432.CCR-12-0408
|
79 |
Niko Hiltunen, Niko Kemi, Juha P. Väyrynen, Jan Böhm, Joonas H. Kauppila, Heikki Huhta, Olli Helminen, Luwen Zhang. Toll-like receptors 1–9 in small bowel neuroendocrine tumors–Clinical significance and prognosis. PLOS ONE 2024; 19(5): e0302813 doi: 10.1371/journal.pone.0302813
|
80 |
Tim De Schutter, Graciela Andrei, Dimitri Topalis, Sophie Duraffour, Tania Mitera, Joost van den Oord, Patrick Matthys, Robert Snoeck. Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Molecular Cancer 2013; 12(1) doi: 10.1186/1476-4598-12-158
|
81 |
Olli Helminen, Heikki Huhta, Petri P. Lehenkari, Juha Saarnio, Tuomo J. Karttunen, Joonas H. Kauppila. Nucleic acid-sensing toll-like receptors 3, 7 and 8 in esophageal epithelium, barrett’s esophagus, dysplasia and adenocarcinoma. OncoImmunology 2016; 5(5): e1127495 doi: 10.1080/2162402X.2015.1127495
|
82 |
Franz Villarroel-Espindola, Troy Ejsmentewicz, Roxana Gonzalez-Stegmaier, Roddy A Jorquera, Esteban Salinas. Intersections between innate immune response and gastric cancer development. World Journal of Gastroenterology 2023; 29(15): 2222-2240 doi: 10.3748/wjg.v29.i15.2222
|
83 |
Dilraj Kaur, Chakit Arora, Gajendra Pal Singh Raghava. Prognostic Biomarker-Based Identification of Drugs for Managing the Treatment of Endometrial Cancer. Molecular Diagnosis & Therapy 2021; 25(5): 629 doi: 10.1007/s40291-021-00539-1
|
84 |
Suprabhat Mukherjee, Ritwik Patra, Payam Behzadi, Andrea Masotti, Alessandro Paolini, Meysam Sarshar. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1244345
|
85 |
Nilesh Pandey, Alex Chauhan, Neeraj Jain. TLR4 Polymorphisms and Expression in Solid Cancers. Molecular Diagnosis & Therapy 2018; 22(6): 683 doi: 10.1007/s40291-018-0361-9
|
86 |
Sophia Ran, Nihit Bhattarai, Radhika Patel, Lisa Volk-Draper. Translational Studies on Inflammation. 2020; doi: 10.5772/intechopen.85195
|
87 |
Keita Kouzu, Hironori Tsujimoto, Yoji Kishi, Hideki Ueno, Nariyoshi Shinomiya. Bacterial Translocation in Gastrointestinal Cancers and Cancer Treatment. Biomedicines 2022; 10(2): 380 doi: 10.3390/biomedicines10020380
|
88 |
Emna Fehri, Emna Ennaifer, Monia Ardhaoui, Kaouther Ouerhani, Thalja Laassili, Rahima Bel Haj Rhouma, Ikram Guizani, Samir Boubaker. Expression of Toll-like Receptor 9 Increases with Progression of Cervical Neoplasia in Tunisian Women - A Comparative Analysis of Condyloma, Cervical Intraepithelial Neoplasia and Invasive Carcinoma. Asian Pacific Journal of Cancer Prevention 2014; 15(15): 6145 doi: 10.7314/APJCP.2014.15.15.6145
|
89 |
Mie Linder Hübbe, Ditte Elisabeth Jæhger, Thomas Lars Andresen, Mads Hald Andersen. Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.578349
|
90 |
Ruibing Su, Lijun Cai, Pan Xiong, Zhiwei Liu, Shaobin Chen, Xi Liu, Runhua Lin, Zhijin Lei, Dongping Tian, Min Su. TLR3 Expression is a Potential Prognosis Biomarker and Shapes the Immune-Active Tumor Microenvironment in Esophageal Squamous Cell Carcinoma. Journal of Inflammation Research 2022; : 1437 doi: 10.2147/JIR.S348786
|
91 |
Valentino Le Noci, Giancarla Bernardo, Francesca Bianchi, Elda Tagliabue, Michele Sommariva, Lucia Sfondrini. Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. Frontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.732192
|
92 |
Harikumar Pallathadka, Abdulrahman Qais Khaleel, Ahmed Hussein Zwamel, H. Malathi, Snehlata Sharma, Jasur Alimdjanovich Rizaev, Yasser Fakri Mustafa, Atreyi Pramanik, Mahmood Hasen Shuhata Alubiady, Mohammed Abed Jawad. Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling. Cell Biochemistry and Biophysics 2024; doi: 10.1007/s12013-024-01418-2
|
93 |
Liying Yang, Fritz Francois, Zhiheng Pei. Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus. Clinical Cancer Research 2012; 18(8): 2138 doi: 10.1158/1078-0432.CCR-11-0934
|